{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:41Z","timestamp":1793727761865,"version":"4.6.1"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2024.116169","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T12:49:56Z","timestamp":1705322996000},"page":"116169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Effects of telmisartan on metabolic syndrome components: a comprehensive review"],"prefix":"10.1016","volume":"171","author":[{"given":"Mohsen","family":"Imenshahidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Roohbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib1","first-page":"557","article-title":"A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome","volume":"20","author":"Tabeshpour","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40618-021-01720-3","article-title":"Effects of glycine on metabolic syndrome components: a review","volume":"45","author":"Imenshahidi","year":"2022","journal-title":"J. Endocrinol. Invest"},{"issue":"11","key":"10.1016\/j.biopha.2024.116169_bib3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.CIR.0000141736.76561.78","article-title":"Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome","volume":"110","author":"Prasad","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.116169_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00210-020-01822-4","article-title":"Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review","volume":"393","author":"Imenshahidi","year":"2020","journal-title":"Naunyn-Schmiede 'S. Arch. Pharmacol."},{"issue":"22","key":"10.1016\/j.biopha.2024.116169_bib5","doi-asserted-by":"crossref","first-page":"12490","DOI":"10.1073\/pnas.93.22.12490","article-title":"Cross-talk between the insulin and angiotensin signaling systems","volume":"93","author":"Velloso","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.physbeh.2010.03.018","article-title":"The renin angiotensin system and the metabolic syndrome","volume":"100","author":"de Kloet","year":"2010","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2024.116169_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2015.04.019","article-title":"Comparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in rats","volume":"760","author":"Rabie","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-010-2002-9","article-title":"Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine","volume":"213","author":"Yamashita","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2024.116169_bib9","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2147\/DMSO.S265399","article-title":"Anti-diabetic effect of telmisartan through its partial PPAR\u03b3-agonistic activity","volume":"13","author":"Ayza","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2024.116169_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/DMSO.S187092","article-title":"Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report","volume":"11","author":"Cheng","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1139\/cjpp-2016-0090","article-title":"Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats","volume":"94","author":"Shahataa","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116169_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/VHRM.S7857","article-title":"New standards in hypertension and cardiovascular risk management: focus on telmisartan","volume":"6","author":"Galzerano","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jash.2013.02.006","article-title":"Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome","volume":"7","author":"Takagi","year":"2013","journal-title":"J. Am. Soc. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib14","first-page":"909","article-title":"Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus","volume":"15","author":"Chen","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/hr.2014.148","article-title":"Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure","volume":"38","author":"Peng","year":"2015","journal-title":"Hypertens. Res"},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3851\/IMP1809","article-title":"Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients","volume":"16","author":"Vecchiet","year":"2011","journal-title":"Antivir. Ther."},{"issue":"12a","key":"10.1016\/j.biopha.2024.116169_bib17","article-title":"Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease","volume":"91","author":"McFarlane","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J. Int. Med. Res."},{"issue":"10","key":"10.1016\/j.biopha.2024.116169_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0090-9556(24)15038-6","article-title":"Disposition and chemical stability of telmisartan 1-O-acylglucuronide","volume":"27","author":"Ebner","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/00005344-200111000-00004","article-title":"Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge","volume":"38","author":"Stangier","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116169_bib22","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2147\/DMSO.S265399","article-title":"Anti-diabetic effect of telmisartan through its partial PPAR\u03b3-agonistic activity","volume":"13","author":"Ayza","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2337\/diacare.27.4.1015","article-title":"Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease","volume":"27","author":"Pershadsingh","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116169_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib25","first-page":"166","article-title":"Thiazolidinedione derivatives in type 2 diabetes mellitus","volume":"64","author":"Tack","year":"2006","journal-title":"Neth. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2011.05.009","article-title":"Adiponectin is required for PPAR\u03b3-mediated improvement of endothelial function in diabetic mice","volume":"14","author":"Wong","year":"2011","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib27","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","article-title":"Submaximal PPAR\u03b3 activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders","volume":"166","author":"Balakumar","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.metabol.2004.11.017","article-title":"Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty","volume":"54","author":"Wang","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2024.116169_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/VHRM.S59429","article-title":"Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril","volume":"10","author":"Wang","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036297","article-title":"Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) \u03b3 activators and pan-PPAR partial agonists","volume":"7","author":"Liberato","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/0971-6580.103660","article-title":"Evaluation of acute toxicity of pioglitazone in mice","volume":"19","author":"Chinnam","year":"2012","journal-title":"Toxicol. Int."},{"key":"10.1016\/j.biopha.2024.116169_bib32","unstructured":"(MD) B. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].): Telmisartan. [.].: National Institute of Diabetes and Digestive and Kidney Diseases; 2017."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2007.12.036","article-title":"A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects","volume":"584","author":"Chang","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/dmrr.1187","article-title":"Efficacy and safety of the PPAR\u03b3 partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy","volume":"27","author":"Henriksen","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/cbdd.12806","article-title":"Multitargeted bioactive ligands for PPARs discovered in the last decade","volume":"88","author":"Zhang","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2024.116169_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.brainres.2010.07.017","article-title":"Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia","volume":"1353","author":"Haraguchi","year":"2010","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/hr.2012.17","article-title":"Structural basis for telmisartan-mediated partial activation of PPAR gamma","volume":"35","author":"Amano","year":"2012","journal-title":"Hypertens. Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.109.132886","article-title":"Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation","volume":"54","author":"Kappert","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4682-3-1","article-title":"Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b","volume":"3","author":"Marshall","year":"2006","journal-title":"Theor. Biol. Med. Model."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ajh\/hpt019","article-title":"Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan","volume":"26","author":"Z\u00eddek","year":"2013","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","article-title":"PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin","volume":"46","author":"Clasen","year":"2005","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/HYPERTENSIONAHA.112.192401","article-title":"Peroxisome proliferator-activated receptor-\u03b3 activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice","volume":"59","author":"Min","year":"2012","journal-title":"Hypertension"},{"issue":"1-3","key":"10.1016\/j.biopha.2024.116169_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejphar.2012.11.022","article-title":"Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice","volume":"698","author":"Ushijima","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib44","article-title":"Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cpt.1928","article-title":"UGT1A3 and sex are major determinants of telmisartan pharmacokinetics-a comprehensive pharmacogenomic study","volume":"108","author":"Hirvensalo","year":"2020","journal-title":"Clin. Pharm. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.116169_bib46","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J. Hum. Hypertens."},{"issue":"12 Pt 1","key":"10.1016\/j.biopha.2024.116169_bib47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/009127000004001202","article-title":"Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2133\/dmpk.19.15","article-title":"Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method","volume":"19","author":"Tatami","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib49","first-page":"56","article-title":"Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex","volume":"7","author":"Haenisch","year":"2007","journal-title":"Pharm. J."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int J. Toxicol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib51","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","article-title":"Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients","volume":"82","author":"Naesens","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.clpt.6100019","article-title":"Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein","volume":"81","author":"de Jong","year":"2007","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib54","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"2-3","key":"10.1016\/j.biopha.2024.116169_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.biopha.2024.116169_bib56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FPC.0b013e3283482502","article-title":"The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers","volume":"21","author":"Yamada","year":"2011","journal-title":"Pharm. Genom."},{"issue":"11","key":"10.1016\/j.biopha.2024.116169_bib57","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/jms.938","article-title":"Glycosylation site analysis of human alpha-1-acid glycoprotein (AGP) by capillary liquid chromatography-electrospray mass spectrometry","volume":"40","author":"Imre","year":"2005","journal-title":"J. Mass Spectrom."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib58","first-page":"229","article-title":"Antihypertensive medications and blood sugar: theories and implications","volume":"22","author":"Blackburn","year":"2006","journal-title":"Can. J. Cardiol."},{"issue":"20","key":"10.1016\/j.biopha.2024.116169_bib59","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch. Intern Med"},{"key":"10.1016\/j.biopha.2024.116169_bib60","first-page":"677","article-title":"Telmisartan and cardioprotection","volume":"7","author":"Akhrass","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"issue":"15","key":"10.1016\/j.biopha.2024.116169_bib61","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.biopha.2024.116169_bib62","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1592\/phco.26.9.1297","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis","volume":"26","author":"McCall","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"17","key":"10.1016\/j.biopha.2024.116169_bib63","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/jpet.113.211722","article-title":"Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor \u03b3 among clinically used angiotensin II receptor blockers: drug-target interaction analyses","volume":"349","author":"Kakuta","year":"2014","journal-title":"J. Pharm. Exp. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib65","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib66","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity","volume":"54","author":"Schupp","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib67","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/en.2010-1312","article-title":"Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice","volume":"152","author":"Fujisaka","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2024.116169_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1228525","article-title":"Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model","volume":"14","author":"Abd-Eltawab Tammam","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib69","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/j.bbrc.2018.08.091","article-title":"Effects of telmisartan on TNF\u03b1 induced PPAR\u03b3 phosphorylation and insulin resistance in adipocytes","volume":"503","author":"Fang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcjd.2013.03.024","article-title":"Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action","volume":"37","author":"Zhao","year":"2013","journal-title":"Can. J. Diabetes"},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.metabol.2011.06.007","article-title":"Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats","volume":"61","author":"Younis","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2024.116169_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-4-6","article-title":"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome","volume":"4","author":"Vitale","year":"2005","journal-title":"Cardiovasc. Diabetol."},{"issue":"36","key":"10.1016\/j.biopha.2024.116169_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030496","article-title":"Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: a randomized multicenter trial","volume":"101","author":"Lee","year":"2022","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib74","article-title":"Comparative study of the effects of azilsartan and telmisartan on insulin resistance and metabolic biomarkers in essential hypertension associated with type 2 diabetes mellitus","volume":"14","author":"Meher","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/met.2018.0129","article-title":"Even short-term telmisartan treatment ameliorated insulin resistance but had no influence on serum adiponectin and tumor necrosis factor-alpha levels in hypertensive patients with metabolic syndrome","volume":"17","author":"Kiyici","year":"2019","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib76","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12325-011-0040-2","article-title":"Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE)","volume":"28","author":"Mori","year":"2011","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib78","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1097\/MJT.0000000000000733","article-title":"Telmisartan improves insulin resistance: a meta-analysis","volume":"25","author":"Wang","year":"2018","journal-title":"Am. J. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1291\/hypres.30.49","article-title":"Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome","volume":"30","author":"Bahadir","year":"2007","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib80","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00213-019-5181-z","article-title":"Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial","volume":"236","author":"Fan","year":"2019","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.biopha.2024.116169_bib81","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1751-7176.2010.00335.x","article-title":"Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension","volume":"12","author":"Hsueh","year":"2010","journal-title":"J. Clin. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib82","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(11)70611-9","article-title":"Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats","volume":"63","author":"Goyal","year":"2011","journal-title":"Pharm. Rep."},{"issue":"2-3","key":"10.1016\/j.biopha.2024.116169_bib83","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejphar.2011.04.008","article-title":"Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor \u03b3 in 3T3-L1 adipocytes","volume":"660","author":"Furukawa","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cbf.3383","article-title":"Telmisartan protects against high glucose\/high lipid-induced apoptosis and insulin secretion by reducing the oxidative and ER stress","volume":"37","author":"Wang","year":"2019","journal-title":"Cell. Biochem. Funct."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/hr.2012.189","article-title":"Does the PPAR-\u03b3-activating property of telmisartan provide a benefit in clinical practice?","volume":"36","author":"Fujimura","year":"2013","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0430-5","article-title":"Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor \u03b4 (PPAR\u03b4): from bedside to bench","volume":"15","author":"Chang","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib87","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/db12-0570","article-title":"Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-\u03b4 activation","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib88","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/abbs\/gmab049","article-title":"Autoantibody against angiotensin II type I receptor induces pancreatic \u03b2-cell apoptosis via enhancing autophagy","volume":"53","author":"Wang","year":"2021","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00592-010-0210-8","article-title":"Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet","volume":"50","author":"Yuan","year":"2013","journal-title":"Acta Diabetol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib90","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000334951","article-title":"Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension","volume":"35","author":"Kubik","year":"2012","journal-title":"Kidney Blood Press. Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib91","doi-asserted-by":"crossref","first-page":"321","DOI":"10.36740\/WLek202002122","article-title":"The effect of therapy with olmesartan or telmisartan in patients with arterial hypertension combined with obesity","volume":"73","author":"Bochar","year":"2020","journal-title":"Wiad. Lek."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12325-012-0032-x","article-title":"Telmisartan at 80 mg\/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients","volume":"29","author":"Mori","year":"2012","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2024.116169_bib93","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF03261912","article-title":"Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study","volume":"32","author":"Hamamoto","year":"2012","journal-title":"Clin. Drug Investig."},{"issue":"11","key":"10.1016\/j.biopha.2024.116169_bib94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1291\/hypres.29.849","article-title":"Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-\u03b1","volume":"29","author":"Derosa","year":"2006","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2024.116169_bib95","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1590\/S0004-27302011000500010","article-title":"Metabolic improvement by telmisartan beyond angiotensin receptor blockade: Role of adipokines","volume":"55","author":"Sahebkar","year":"2011","journal-title":"Arq. Bras. De. Endocrinol. e Metabol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib96","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"Derosa","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.HYP.0000225402.69580.1d","article-title":"Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice","volume":"48","author":"Araki","year":"2006","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.biopha.2024.116169_bib98","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2362.2008.02025.x","article-title":"Angiotensin inhibition stimulates PPARgamma and the release of visfatin","volume":"38","author":"Storka","year":"2008","journal-title":"Eur. J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11596-011-0374-7","article-title":"Telmisartan protects against insulin resistance by attenuating inflammatory response in rats","volume":"31","author":"Xu","year":"2011","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.biopha.2024.116169_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-9-64","article-title":"PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice","volume":"9","author":"Foryst-Ludwig","year":"2010","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2024.116169_bib101","article-title":"Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPAR\u03b3","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116169_bib102","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-11-139","article-title":"Telmisartan ameliorates insulin sensitivity by activating the AMPK\/SIRT1 pathway in skeletal muscle of obese db\/db mice","volume":"11","author":"Shiota","year":"2012","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2024.116169_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112563","article-title":"AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation","volume":"146","author":"Entezari","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116169_bib104","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mce.2016.10.021","article-title":"Differential effects of angiotensin receptor blockers on pancreatic islet remodelling and glucose homeostasis in diet-induced obese mice","volume":"439","author":"Graus-Nunes","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"issue":"Suppl 4(Suppl 4)","key":"10.1016\/j.biopha.2024.116169_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1463-1326.2009.01121.x","article-title":"Pdx1 and other factors that regulate pancreatic beta-cell survival","volume":"11","author":"Fujimoto","year":"2009","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib106","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1081\/CEH-200067668","article-title":"Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements","volume":"27","author":"Nishimura","year":"2005","journal-title":"Clin. Exp. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00126097-200408000-00005","article-title":"Sustained antihypertensive activity of telmisartan compared with valsartan","volume":"9","author":"Lacourci\u00e8re","year":"2004","journal-title":"Blood Press. Monit."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib108","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ahj.2005.02.014","article-title":"Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting","volume":"151","author":"White","year":"2006","journal-title":"Am. Heart J."},{"issue":"10","key":"10.1016\/j.biopha.2024.116169_bib109","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.4103\/jfmpc.jfmpc_787_22","article-title":"Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: a meta-analysis","volume":"11","author":"Kumari","year":"2022","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/hr.2013.141","article-title":"Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy","volume":"37","author":"Yoshida","year":"2014","journal-title":"Hypertens. Res."},{"issue":"1 Suppl","key":"10.1016\/j.biopha.2024.116169_bib111","article-title":"Telmisartan in high-risk cardiovascular patients","volume":"105","author":"Weber","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib112","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00004872-200205000-00020","article-title":"The morning surge in blood pressure and heart rate is dependent on levels of physical activity after waking","volume":"20","author":"Leary","year":"2002","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib113","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0149-2918(02)85026-3","article-title":"Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis","volume":"24","author":"Iskedjian","year":"2002","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/jhh.2008.132","article-title":"Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials","volume":"23","author":"Zou","year":"2009","journal-title":"J. Hum. Hypertens."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ajh.2008.30","article-title":"Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension","volume":"21","author":"Xi","year":"2008","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.hjh.0000194364.11516.ab","article-title":"The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)","volume":"24","author":"Williams","year":"2006","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib117","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.jhh.1001494","article-title":"Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study","volume":"16","author":"Ragot","year":"2002","journal-title":"J. Hum. Hypertens."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib118","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/hr.2013.121","article-title":"Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies","volume":"37","author":"Gosse","year":"2014","journal-title":"Hypertens. Res."},{"issue":"15","key":"10.1016\/j.biopha.2024.116169_bib119","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib120","doi-asserted-by":"crossref","DOI":"10.1177\/1470320316674876","article-title":"Inhibitory effects of telmisartan on culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4+ T lymphocytes from Xinjiang Kazakh patients with hypertension","volume":"17","author":"Huang","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/hr.2015.2","article-title":"Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension","volume":"38","author":"Furuhashi","year":"2015","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2024.116169_bib122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.peptides.2014.03.014","article-title":"Comparision of secretagogue effects of rosiglitazone and telmisartan on ANP secretion in rats","volume":"56","author":"Gao","year":"2014","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.biopha.2024.116169_bib123","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1097\/HJH.0b013e328357fa98","article-title":"Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats","volume":"30","author":"Konno","year":"2012","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib124","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ajh\/hpu076","article-title":"Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity","volume":"27","author":"Sueta","year":"2014","journal-title":"Am. J. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.33549\/physiolres.932433","article-title":"Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K\/Akt\/eNOS pathway and NO release in spontaneously hypertensive rats","volume":"62","author":"Xu","year":"2013","journal-title":"Physiol. Res"},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib126","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/hr.2010.107","article-title":"Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan","volume":"33","author":"Wago","year":"2010","journal-title":"Hypertens. Res."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib127","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11906-014-0463-7","article-title":"The Role of Adiponectin in Endothelial Dysfunction and Hypertension","volume":"16","author":"Rojas","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.atherosclerosis.2005.08.009","article-title":"Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice","volume":"186","author":"Takaya","year":"2006","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3317\/jraas.2003.039","article-title":"Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers","volume":"4","author":"Vingerhoedt","year":"2003","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3317\/jraas.2002.038","article-title":"Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension","volume":"3","author":"Asmar","year":"2002","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib131","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/10641963.2018.1529781","article-title":"Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension","volume":"41","author":"Zhu","year":"2019","journal-title":"Clin. Exp. Hypertens."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib132","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2337\/dc06-1551","article-title":"Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes","volume":"30","author":"Schmieder","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib133","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbrc.2011.06.012","article-title":"Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-\u03b3-dependent activity","volume":"410","author":"Toyama","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2024.116169_bib134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2840-12-30","article-title":"AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPAR\u03b3","volume":"12","author":"Tiyerili","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4149\/gpb_2022039","article-title":"Homocysteine promotes migration of adventitial fibroblasts via angiotensin II type 1 receptor activation to aggravate atherosclerosis","volume":"41","author":"Zhu","year":"2022","journal-title":"Gen. Physiol. Biophys."},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib136","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"35","key":"10.1016\/j.biopha.2024.116169_bib137","article-title":"Activation of AMPK by telmisartan decreases basal and PDGF-stimulated VSMC proliferation via Inhibiting the mTOR\/p70S6K signaling axis","volume":"35","author":"Hwang","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000500038","article-title":"Angiotensin II receptor type 1 antagonists modulate vascular smooth muscle cell proliferation and migration via AMPK\/mTOR","volume":"143","author":"Zhao","year":"2019","journal-title":"Cardiology"},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib139","first-page":"2200","article-title":"Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation","volume":"125","author":"Wang","year":"2012","journal-title":"Chin. Med. J."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib140","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s00380-018-01338-1","article-title":"The effect of Telmisartan on the expression of connexin43 and neointimal hyperplasia in a rabbit iliac artery restenosis model","volume":"34","author":"Cao","year":"2019","journal-title":"Heart Vessels"},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib141","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.3892\/mmr.2017.7177","article-title":"Telmisartan improves vascular remodeling through ameliorating prooxidant and profibrotic mechanisms in hypertension via the involvement of transforming growth factor-\u03b21","volume":"16","author":"Shang","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"15","key":"10.1016\/j.biopha.2024.116169_bib142","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1042\/CS20170131","article-title":"AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice","volume":"131","author":"Krueger","year":"2017","journal-title":"Clin. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib143","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/hr.2012.196","article-title":"Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials","volume":"36","author":"Takagi","year":"2013","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2024.116169_bib144","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vph.2015.10.001","article-title":"Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNF\u03b1-stimulated endothelial cells by inhibiting IKK\u03b2 expression","volume":"78","author":"Song","year":"2016","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib145","first-page":"65","article-title":"Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-\u03b1","volume":"48","author":"Cicha","year":"2011","journal-title":"Clin. Hemorheol. Micro"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib146","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11033-014-3757-6","article-title":"Telmisartan-induced PPAR\u03b3 activity attenuates lipid accumulation in VSMCs via induction of autophagy","volume":"42","author":"Li","year":"2015","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2024.116169_bib147","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2015.06.005","article-title":"Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs","volume":"762","author":"Xu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116169_bib148","article-title":"Effect of telmisartan on blood pressure and lipid profile in hypertensive patients with dyslipidemia","volume":"4","author":"Jayapriya","year":"2013","journal-title":"Int. J. Pharm. Life Sci."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib149","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1291\/hypres.27.457","article-title":"Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study","volume":"27","author":"Derosa","year":"2004","journal-title":"Hypertens. Res."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib150","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib151","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5152\/tjg.2020.19365","article-title":"Effects of orlistat or telmisartan on the serum free fatty acids in non-alcoholic fatty liver disease patients: an open-labeled randomized controlled study","volume":"33","author":"Wasta Esmail","year":"2022","journal-title":"Turk. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib152","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2337\/db07-0839","article-title":"Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan","volume":"57","author":"Clemenz","year":"2008","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib153","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/07435800.2013.828741","article-title":"Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells","volume":"39","author":"Yin","year":"2014","journal-title":"Endocr. Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib154","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0003319713512556","article-title":"Combining rosuvastatin with angiotensin-receptor blockers of different PPAR\u03b3-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes","volume":"66","author":"Rizos","year":"2015","journal-title":"Angiology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2710.2010.01161.x","article-title":"Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan","volume":"36","author":"Inoue","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib156","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/157016111794519291","article-title":"Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-\u03b3","volume":"9","author":"Nakagami","year":"2011","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116169_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.682726","article-title":"Inhibition of the renin-angiotensin system reduces gene expression of inflammatory mediators in adipose tissue independent of energy balance","volume":"12","author":"Mitchell","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib158","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-021-01259-w","article-title":"Countering adipose tissue dysfunction could underlie the superiority of telmisartan in the treatment of obesity-related hypertension","volume":"20","author":"Naguib","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib159","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4254\/wjh.v11.i4.359","article-title":"Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model","volume":"11","author":"Graus-Nunes","year":"2019","journal-title":"World J. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116169_bib160","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1111\/j.1476-5381.2011.01726.x","article-title":"Double blockade of angiotensin II (AT(1))-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats","volume":"165","author":"Miesel","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib161","doi-asserted-by":"crossref","first-page":"H599","DOI":"10.1152\/ajpheart.00101.2013","article-title":"Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats","volume":"305","author":"V\u00e1zquez-Medina","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib162","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00210-011-0602-5","article-title":"Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure","volume":"383","author":"M\u00fcller-Fielitz","year":"2011","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116169_bib163","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2840-6-12","article-title":"Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients","volume":"6","author":"Kintscher","year":"2007","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/JOE-19-0319","article-title":"Telmisartan prevents development of obesity and normalizes hypothalamic lipid droplets","volume":"244","author":"Rawish","year":"2020","journal-title":"J. Endocrinol."},{"issue":"15","key":"10.1016\/j.biopha.2024.116169_bib165","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1111\/bph.13172","article-title":"Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)\/Mas-dependent pathway","volume":"172","author":"Schuchard","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib166","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1479164112444640","article-title":"The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)","volume":"10","author":"Murakami","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"issue":"7","key":"10.1016\/j.biopha.2024.116169_bib167","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/03007995.2016.1171204","article-title":"Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials","volume":"32","author":"Choi","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.biopha.2024.116169_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-38399-1","article-title":"Telmisartan induces browning of fully differentiated white adipocytes via M2 macrophage polarization","volume":"9","author":"Jeon","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib169","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/HYPERTENSIONAHA.109.143958","article-title":"Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways","volume":"55","author":"He","year":"2010","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.biopha.2024.116169_bib170","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/15384047.2020.1838032","article-title":"Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6\/JAK\/STAT pathway and can be reversed by telmisartan","volume":"21","author":"Wang","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2024.116169_bib171","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/bph.13461","article-title":"The brain renin-angiotensin system plays a crucial role in regulating body weight in diet-induced obesity in rats","volume":"173","author":"Winkler","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116169_bib172","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.orcp.2010.11.003","article-title":"Telmisartan suppresses food intake in mice via the melanocortin pathway","volume":"5","author":"Noma","year":"2011","journal-title":"Obes. Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib173","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bph.12949","article-title":"Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats","volume":"172","author":"M\u00fcller-Fielitz","year":"2015","journal-title":"Br. J. Pharmcol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116169_bib174","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00424-018-2178-0","article-title":"Telmisartan prevents diet-induced obesity and preserves leptin transport across the blood-brain barrier in high-fat diet-fed mice","volume":"470","author":"Schuster","year":"2018","journal-title":"Pflug. Arch."},{"issue":"4","key":"10.1016\/j.biopha.2024.116169_bib175","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/1755-5922.12073","article-title":"Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis","volume":"32","author":"Pan","year":"2014","journal-title":"Cardiovasc. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116169_bib176","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijcard.2012.09.044","article-title":"Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials","volume":"165","author":"Takagi","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116169_bib177","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1751-7176.2010.00287.x","article-title":"A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension","volume":"12","author":"Zheng","year":"2010","journal-title":"J. Clin. Hypertens."},{"issue":"5","key":"10.1016\/j.biopha.2024.116169_bib178","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ajh.2008.30","article-title":"Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension","volume":"21","author":"Xi","year":"2008","journal-title":"Am. J. Hypertens."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:38Z","timestamp":1792096778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":178,"alternative-id":["S0753332224000507"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116169","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of telmisartan on metabolic syndrome components: a comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116169"}}